Quick Read
-
RVMD has surged 492% over one year on daraxonrasib’s landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival.
-
MRK ranks as the most likely acquirer, with Keytruda’s patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio.
-
It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor)
Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform a market cap of $44.1 billion. The stock is up 158.1% year to date, 492.4% over one year, and 664.1% over five years. Liquidity stands at $3.94 billion in cash and marketable securities, bolstered by $2.23 billion in spring 2026 capital raises and up to an additional $1.5 billion available under Royalty Pharma arrangements. FY2026 GAAP operating expenses are guided to $2.10 billion to $2.20 billion. There is no product revenue yet, EPS runs at −$8.87 for the trailing 12 months, and no deal talks have been confirmed.
Why a Strategic Buyer Would Want It
RAS mutations drive roughly 30% of cancers, and Revolution has the deepest late-stage RAS(ON) pipeline in biotech. Lead asset daraxonrasib delivered median overall survival of 13.2 months versus 6.7 months for chemo in second-line pancreatic cancer (HR 0.40; p<0.0001). The FDA accepted the NDA and granted Priority Voucher review. CEO Mark Goldsmith called it “a transformational period” tied to “unprecedented Phase 3 results.” Elironrasib (85% ORR in 1L G12C NSCLC), zoldonrasib (82% ORR in G12D NSCLC), and RMC-5127 underscore the scarcity case.
Ranking the Plausible Acquirers
5. Pfizer (NYSE:PFE). CEO Albert Bourla says, “I’m particularly encouraged by what we’re seeing in oncology.” With EBITDA of $25.38 billion and a stretched balance sheet post-Seagen, a more than $50 billion check is a reach.
SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $3,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now. (Sponsor)
4. Johnson & Johnson (NYSE:JNJ). It has a $626.1 billion market cap, AAA credit, and a stated $50 billion oncology target by 2030. The company already bought Firefly Bio for KRAS degraders. Discipline on price is the offset.
3. Bristol Myers Squibb (NYSE:BMY). Owns Krazati (KRAS G12C) and has an existing clinical collaboration on daraxonrasib plus navlimetostat. The strategic fit is tightest. Net debt near $33.6 billion is the constraint.
